Biocon Meets $650m Equity Infusion In Biocon Biologics To Fund Viatris Buy

Parent Company Invests Another $270m In Biocon Biologics After Earlier Allotment

Financing
Viatris will receive cash and equity for its biosimilars • Source: Shutterstock

More from Biosimilars

More from Products